Could a targeted antibody outdo steroids for a rare kidney disease?
NCT ID NCT07710157
First seen Jul 17, 2026 · Last updated Jul 22, 2026 · Updated 3 times
Summary
This phase IIa trial investigates whether obinutuzumab, a monoclonal antibody, can effectively treat adults with newly diagnosed minimal change disease, a kidney condition causing protein leakage and swelling. Participants receive either two doses of obinutuzumab or standard glucocorticoid therapy, with the goal of inducing remission and preventing relapses over 52 weeks. The study compares the two treatments for safety and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- obinutuzumab, a monoclonal antibody drug
- What this could lead to
- If successful, this could offer a new treatment option for adults with minimal change disease, potentially reducing relapses compared to standard steroids.
- What could go wrong
- This is an early-phase trial with only 48 participants, so results may not be conclusive. Obinutuzumab may cause side effects like infusion reactions or infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MINIMAL CHANGE DISEASE (MCD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
6. Medizinische Abteilung mit Nephrologie & Dialyse, Klinik Ottakring
NOT_YET_RECRUITINGVienna, 1160, Austria
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Department of Internal Medicine IV, Nephrology and Hypertension
RECRUITINGInnsbruck, 6020, Austria
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Email: •••••@•••••
-
Division of Nephrology, Department of Internal Medicine, Medical University of Graz
NOT_YET_RECRUITINGGraz, 8036, Austria
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital Henri-Mondor
NOT_YET_RECRUITINGParis, 94000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
III. Department of Medicine, University Medical Center Hamburg-Eppendorf
NOT_YET_RECRUITINGHamburg, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Laboratory of Immunology, Nice University Hospital (CHU de Nice), Côte d'Azur University
NOT_YET_RECRUITINGNice, 06003, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.